Genomma Lab Internacional SAB de CV Class B · BMV:LAB/B

Genomma Lab Internacional SAB de CV Class B — Investor Presentation (November 2014)

26 slides from Genomma Lab Internacional SAB de CV Class B's investor presentation, November 2014

  1. Slide 1: Corporate Presentation November 2014

    Slide 1: Corporate Presentation November 2014

    EXPORTING WELL- NOVEMBER 2014) 3 S +s : LATAM

  2. Slide 2: Company Overview

    Slide 2: Company Overview

    NVEIOEIOOIOD Fi aS | b ee | | 5 Fee Noma SS Sistema 4 | Ge | SON Iran a 7 | ye “ | vince I AL \ J ' BoA EN _2. COMPAN OVERVIEW 9)" (9

  3. Slide 3: Company history and acquisitions

    Slide 3: Company history and acquisitions

    Acquisition of 2 packages of brands in our international operations Entrance to IPC Sustainability Index and MSCI Index Acquisition of the brands: Fermodyl, Zan Zusi, Altiva, Amara, Larizá, Bioskin and XL-3 in Mexico, Babysan and Piecidex in Argentina and Dermaglós in Brazil Acquisition of Marzam Ac

  4. Slide 4: IPO and index inclusion

    Slide 4: IPO and index inclusion

    ¢ In 2008, Genomma Lab conducted its Initial Public Offering in the Mexican Stock Exchange (BMV). ¢ In 2010, it entered the Mexican Stock Index (IPC) of the BMV. ¢Genomma Lab is one of the most liquid companies in the BMV. ¢ The Company is part of the MSCI EM LATAM Mid Cap Index and MSCI Mexico Stan

  5. Slide 5: Unique product development and innovation capabilities

    Slide 5: Unique product development and innovation capabilities

    Bo UNIQUE PRODUCT DEVELOPMENT AND INNOVATION CAPABILITIES Genomma Lab (“Genomma”) is a leading Pharmaceutical and Personal Care products (“PC”) company in Mexico with international operations in Latin America and the United States. It is one of the fastest growing companies in the industry. S vi IN-

  6. Slide 6: Manufacturing and product development pillars

    Slide 6: Manufacturing and product development pillars

    Best formulation and Performance presentation Analysis (Product Selection) MANUFACTURING DEVELOPMENT INNOVATION & MARKETING & DISTRIBUTION OUTSOURCED ASSURANCE BRANDING QUALITY SALES Impressively short lead time Rapid and effective from an idea generation to new reaction to competitive product launc

  7. Slide 7: SKUs

    Slide 7: SKUs

    Offers branded OTC Offers over 100 Focuses on topical pharmaceuticals in SKU’s under the dermatological, facial variety of forms brand Primer Nivel and hair treatments Por Tu Salud and other categories - Inhibitors of gastric - Varicose vein secretions - Anti-rheumatics treatment - Hemorrhoid - Anti

  8. Slide 8: Top 25 brands

    Slide 8: Top 25 brands

    Genomma's core asset is its portfolio of market leading brands. As of September 2014, the Company has a total of 91 brands. The following table shows the Company’s top 25 brands for the last twelve months as of September 2014, which represented 82.1% of Total Sales. Sexual Protection and Anti-scar,

  9. Slide 9: Advertising strategy

    Slide 9: Advertising strategy

    Demand for our products is mainly generated through advertising. We have a directed advertising strategy, based on metric analyses of our clients and the market. We monitor such information weekly, which allows us to have a quick response to changes in competition and consumer’s preferences.

  10. Slide 10: Competitive Position

    Slide 10: Competitive Position

    | 2. COMPETIT POSITION = Duele (]

  11. Slide 11: Market position versus competitors

    Slide 11: Market position versus competitors

    (For the last twelve months, as of September 2014) Genomma Lab Bayer Boehringer Sanofi Aventis Shering Plough Pisa Reckitt Benckiser Novartis Wyeth Johnson Johnson Source: IMS Health.

  12. Slide 12: Market share

    Slide 12: Market share

    Source: Company data and IMS Health.

  13. Slide 13: Market share

    Slide 13: Market share

    Source: Company data and IMS Health..

  14. Slide 14: Rankings by country and category

    Slide 14: Rankings by country and category

    OTC – Over the Counter Pharma – OTC and Generics PC Phar m a – Personal Care PC 1. Brazil 2. OTC Argentina PC 3. USA 4. Colombia 5. Chile 6. Peru 7. Ecuador *According to IMS.

  15. Slide 15: Diversified distribution platform

    Slide 15: Diversified distribution platform

    DIVERSIFIED DISTRIBUTION PLATFORM DISTRIBUTION IN MEXICO: 4% 18% 39% *As of September 2014 (LTM) Genomma’s balanced and broad distribution platform is unique. Through a combination of mass merchandisers, pharmacy chains, and wholesalers, Genomma’s products reach over 44,000 points of sale in Mexico,

  16. Slide 16: International operations and brands by country

    Slide 16: International operations and brands by country

    Bolivia Chile Brands: 19 Costa Rica Dominican Republic Ecuador El Salvador Guatemala Honduras Brands: 91 Nicaragua Brands: 13 Panama Paraguay Peru Uruguay Brands: 26 Brands: 12 Brands: 25

  17. Slide 17: Growth strategy

    Slide 17: Growth strategy

    • Innovation & Development • Entrance to new segments • Broad Distribution • Formula Improvement • Line Extensions • Revitalize Acquired Brands • Brand Development • Implement Marketing Capabilities • International Expansion

  18. Slide 18: 3Q14 LTM

    Slide 18: 3Q14 LTM

    *CAGR from 2008 to 2013 2008 2009 2010 2011 2012 2013 3Q14 LTM

  19. Slide 19: Product launches

    Slide 19: Product launches

    Nasal Hygiene For adults For children Nasalub Max Vitamins Energetic beverage Vitamins for with vitamins children

  20. Slide 20: Product launches

    Slide 20: Product launches

    X-Ray with added Calcium and Vitamin D Osteoarthritis treatment for diabetics Osteoarthritis Joint pain treatment relief

  21. Slide 21: Genomma Lab Internacional

    Slide 21: Genomma Lab Internacional

    Genomma Lab’ Internacional

  22. Slide 22: Revenue by segment and region

    Slide 22: Revenue by segment and region

    YoY Growth: 9.5% 2008 2009 2010 2012 2013 2011 3Q13 3Q14 3Q14 3Q13 Pharma* PC Total 3Q14 Pharma* PC Total 3Q13 %Var Mexico 1,339.0 675.6 2,014.6 1,197.7 819.4 2,017.1 -0.1% International 379.0 966.0 1,344.9 240.2 809.4 1,049.6 28.1% TOTAL 1,718.0 1,641.5 3,359.5 1,437.9 1,628.8 3,066.8 9.5%

  23. Slide 23: EBITDA and margin

    Slide 23: EBITDA and margin

    3,500 50.0% 3,000 YoY Growth: 2,500 40.0% 6.8% 2,000 30.0% 1,500 20.0% 1,000 10.0% 500 - 0.0% 2008 2009 2010 2012 2013 2011 3Q13 3Q14 EBITDA EBITDA MARGIN

  24. Slide 24: Quarterly results

    Slide 24: Quarterly results

    1Q12 2Q12 3Q12 4Q12 1Q13 2Q13 3Q13 4Q13 1Q14 2Q14 3Q14

  25. Slide 25: Net income as % of revenue

    Slide 25: Net income as % of revenue

    YoY Growth: 1.3% 2013 2008 2009 2010 2012 2011 3Q13 3Q14 NET INCOME AS % OF REVENUE

  26. Slide 26: Investor relations website

    Slide 26: Investor relations website

    i= =. z www.genommalab.com/inversionistas . ¢

Source: Internet Archive copy of inversionistas.genommalab.com

More decks from Genomma Lab Internacional SAB de CV Class B

All 29 Genomma Lab Internacional SAB de CV Class B decks